Deirdre Lyons Head of Specialty Community Gynaecology Imperial College Healthcare NHS Trust

- Learning Objectives
- How to recognise most common conditions
- How to investigate if required
- What questions to ask
- How to assess
- How to initiate treatment
- When to refer

- Important
- History
- Itchy
- Painful
- Soreness
- Intermittent/ Constant
- 'Rash'
- Red/ White
- Scaly
- Previous treatments
- Associated conditions

- Examination Important to examine
- Evidence of lesions
- Where are the areas of concern?
- Labia Majora
- Labia Minora size
- Vestibule
- Red/ White/ Scaly
- Single/ Multiple lesions
- Pain versus not
- Creases versus not
- Lymph Nodes

- Vulvo-vaginal problems are among 10 leading disorders encountered by primary care clinicians.
- Benign lesions of the vulva are mentioned in three categories :
  - 1. Epithelial conditions.
  - 2. Benign neoplastic disorders.
  - 3. Dermatologic disorders.
- VIN
- Cancer vulva

- Epithelial Conditions
- Lichen simplex .
- Contact Dermatitis
- Lichen sclerosis.
- Lichen planus,
- Erosive lichen planus.

#### **Vulval Disease – Lichen Simplex**

Lichen simplex chronicus "The scratch that itches"

- Chronic eczematous inflammation that results in thickened skin often associated with excoriation and fissures.
- Itch Scratch Itch Cycle
   Often leads to difficulty sleeping
   Scratching may lead to secondary infection

#### **Vulval Disease – Lichen Simplex**



#### **Vulval Disease – Lichen Simplex**



#### Vulval Disease – Lichen Simplex Chronicus

## **Differential Diagnosis LSC**

#### Diseases that cause itching

- Psoriasis
  - More sharply demarcated
  - May include extra-genital locations
- Candidiasis
  - Wet mount or yeast culture
- Lichen sclerosus
  - No scaly appearance
  - May be concurrent condition
- Infestations (lice & scabies)

#### Vulval Disease – Lichen Simplex Chronicus

#### Clinical Findings LSC

PHYSICAL EXAMINATION:

Thick, lichenified skin so labia are enlarged,

rugose +/- edematous

Bilateral or unilateral

Localized to generalized

Color - variably pink, red, violaceous to ruddy brown; often a white appearance will be present when there is a thick keratin layer deposited on the surface of the epithelium

Secondary changes - erosions, ulcer, oozing, fissuring, honey-colored or serosanguineous crusting

#### **Vulval Disease – Lichen Simplex Chronicus**

#### Etiology LSC

LSC develops in several itchy skin conditions: Atopic dermatitis (eczema) Contact dermatitis Lichen sclerosus

Contact dermatitis can start this condition or be the main long-term promoting factor

#### Vulval Disease – Lichen Simplex and Contact Dermatitis



LSC develops in several itchy skin conditions: Atopic dermatitis (eczema) Contact dermatitis Lichen sclerosus

Contact dermatitis can start this condition or be the main long-term promoting factor Vulval Disease – Lichen Simplex Chronicus -Treatment

# Lichen Simplex – nonspecific measures

Improve Skin Barrier Function
 Stop Excessive Hygiene

 Avoid irritants (perfumes, dyes)

 Tepid Soaks

 Soothing, promotes circulation, cleans

 Daily Skin Protection

 "Band-aid" effect (zinc, Vaseline, veg. oil)

 Identify and treat co-existing conditions

### Vulval Disease – Lichen Simplex Chronicus -Treatment

- Remove irritant/ contact allergen if possible
- Break itch-scratch cycle
- Look at various aspects of cleaning etc.
- Bland emollients
- Cetraben
- Steroid ointment –
- Most potent Clobatesol (Dermovate) –
- Topically sparingly b.d. for 8 weeks, then in decreasing dosage
- Dermol washes

#### **Common Vulvar Contactants**

ALLERGENS

Benzocaine (Vagisil) Preservatives Neomycin Latex condoms Chlorhexadine (K-Y) Lanolin (A&D ointment) Perfume Nail Polish IRRITANTS

Soaps/cleansers Sweat, urine, feces Creams (alcohol) Douches Medications – TCA, 5FU Spermicides Panty liners



**Tips: Vulvar Contact Dermatitis** 

**Irritation is the commonest cause** History of contact difficult to elicit

Loss of epidermal barrier from - rash or loss of estrogen increases susceptibility to contact dermatitis

Suspect: allergic if sudden onset of rash irritant if persistent rash

- Treatment/ Management
- Remove irritant/ allergen if known
- Bland emollients
- Dermol washes
- Steroids if required
- Barrier creams



Lichen Sclerosus Introduction

- Common chronic vulvar disease
- Inflammation present
- Age range from childhood to elderly (bimodal distribution)
- Previously termed et atrophicus, now called lichen sclerosus

- Chronic progressive disease which constrict and destroy the normal genital anatomy.
- Longer term, labia minora are lost ,labia majora flatten, clitoris can become inverted .
- Found on the vulva of postmenopausal women
- Can involve all the genital area from mons to anal area.
- Risk of malignant progression 6%



#### Location of Lichen Sclerosus on the Vulva and Adjacent Areas

Labia	100%
Clitoris	70.4%
Perineum	67.9%
Buttocks	32.3%
Perianus	32.1%
Crural area	8.6%
Urethra	3.7%

Lorenz B. Kaufman RH. Kutzner SK. Lichen sclerosus. Therapy with clobetasol propionate. Journal of Reproductive Medicine. 43(9):790-4, 1998

- Can be asymptomatic
- Most common symptom is prirutis
- Can be severe/ intolerable/ interfere with sleep
- Pruritis ani
- OTHER SYMPTOMS
- Burning
- Soreness
- Dyspareunia
- Pain with defaecation
- Constipation

## Signs

- Hypopigmentation
- Ivory white papules or plaques
- Cigarette paper appearance
- Cellophane-like sheen to surface
- Hour glass-figure of eight appearance
- Patchy or generalized
  - Vulva, perineum, perianal
  - No vaginal involvement

Signs Secondary Changes

- Fusion of labia minora
- Scratching yields open areas causing erosions
- Urinary retention
- Tearing

#### Whitening Fusion




#### Loss of Labia Minora



## **Differential Diagnosis**

- Vitiligo
- Lichen planus
- Lichen simplex chronicus
- Vulvar intraepithelial neoplasia (squamous and nonsquamous)
- Psoriasis
- Scarring from laser surgery
- Graft versus host disease
- Tinea



Lymphocytic infiltrate under the band

#### TREATMENT

- Thorough assessment
- Biopsy if any concerns about VIN/ cancer
- Treat any superimposed infection i.e. yeasts
- General Care measures –
- Avoid tight occlusive clothing
- Bland emollients
- 100% cotton underwear
- No soaps on vulva can use Dermol washes

## **Treatment of Lichen Sclerosus**

 Superpotent steroid ointment (clobetasol propionate 0.05%)
 – Twice daily in a thin, invisible film for 1 month then daily for two months

#### • Maintenance

- May require Clobatesol twice a week
- Decrease to Clobatesone? Or less potent steroid
- Aim of treatment to treat symptoms and to halt destruction of labia/ vulva by lichen sclerosis
- ??Decrease risk of transformation to VIN

- Other treatments
- Topical Tacrolimus
- Oral Steroids rarely required
- Side effects
- Intralesional injections steroids
- Retinoids
- Anti-malarial agents chloroquine
- Oral in intralesional

- Surgical Treatment
- Limited role
- Healing
- Recurrence
- Surgical Division of mucosal adhesions helpful in clitoral phimosis
- Surgical division of introital narrowing or labia if unable to pass urine

## **Vulval Disease – Lichen Planus**

# Lichen Planus

- T-cell mediated autoimmune response to an unknown antigen
- Histology and morphology resemble other hyperimmune conditions
- May be found with ulcerative colitis, alopecia areata, vitiligo, morphea, dermatomyositis, LS, and myasthenia gravis

# Vulval disease – Lichen Planus

**Erosive lichen planus** 

# Vulval Disease – Lichen Planus

# Lichen Planus Disease Course

- Erosive mucosal LP typically chronic course with waxing and waning
- Progression to vulvovaginalgingival scarring is common
- SCC is recognized risk but rare
   Estimated to be between 1% and 2%
- Nonresponsive lesions should be biopsied.


# Vulval Disease – Lichen Planus

- Lichen planus can affect oral/ vaginal area
- Importance of examining oral cavity in patient's suspected of lichen planus
- Goal of treatment is relieve symptoms and prevent disease progression and complications
- Remission induction and maintenance
- Can usually be treated with topical agents
- Oral agents for severe cases


# Vulval Disease – Lichen Planus

- Topical Steroids potent first line therapy
- Clobatesol 0.05 ointment
- Initially topically twice a day
- May require maintenance
- Can require topical tacrolimus
- Intravaginal steroid

## Vulval Disease – Erosions and Ulcers



- Superficial or deep epidermis
- Not past basal layer



- Always secondary
- Full thickness extending into dermis or deeper

# Vulval Disease – Erosions


#### **Erosions**

Common	Uncommon	Rare
<ul><li>Excoriation</li><li>Fissures</li></ul>	<ul> <li>Allergic contact dermatitis</li> </ul>	<ul> <li>Hailey-Hailey disease</li> </ul>
<ul><li>Lichen simplex</li><li>Herpes simplex</li></ul>	<ul><li>Post-coital fissures</li><li>Herpes zoster</li></ul>	<ul> <li>Extramammary Paget dis.</li> </ul>
Candidiasis     Erosive lichen	<ul> <li>Stevens Johnson syndrome</li> </ul>	<ul> <li>Toxic epidermal Necrolysis</li> </ul>
sclerosus	Pemphigus	
<ul> <li>Erosive lichen planus</li> </ul>	<ul><li>Pemphigoid</li><li>Cicatricial pemphigoid</li></ul>	
<ul><li>Impetigo</li><li>Irritant contact</li></ul>	<ul> <li>Pemphigoid gestations</li> </ul>	
dermatitis	<ul> <li>Eroded malignancy</li> <li>Plasma cell vulvitis.</li> </ul>	

# Vulval Disease - Ulcers


#### Ulcers

Common	Uncommon	Rare
<ul> <li>Aphthous ulcers, idiopathic</li> </ul>	<ul> <li>Primary syphilis (chancre)</li> </ul>	<ul> <li>Granuloma inguinale</li> </ul>
<ul> <li>Aphthous ulcers 2° to infection or inflammatory disease</li> <li>Crohn's disease</li> <li>HSV in immunosuppressed</li> </ul>	<ul> <li>Trauma, accidental and self- induced</li> <li>Ulcerated malignancy</li> <li>Pyoderma gangrenosum</li> </ul>	<ul> <li>Chancroid</li> <li>Behçet's disease</li> </ul>



# Vulval Disease - Ulcers

#### Vulvar Ulcers - Diagnostic Algorithm



#### Two Types of VIN

VIN (usual) (Warty-Basaloid)

- HPV associated
   HPV 16 most common
- Often multifocal
  - Associated with CIN, VaIN, AIN
- Mean age 30
- Increasing incidence
- 3-10% develop SCC


VIN (Differentiated) (Simplex)

- Not HPV associated
- Often unifocal
- Associated with longstanding LS
- Average age 67
- 2-10% of VIN
- Most diagnosed adjacent to or in follow-up of SCC

**VIN: Clinical Presentation** 

van Seters et. al. Gynecol Oncol 2005;97:645-651

- Based on review of 3322 published patients
- Symptomatic: 64%
  - Vulvar pruritis, burning, superficial discomfort, dyspareunia
- Dx made on finding visible lesion: 30%
- Multifocal: 49%
- Multicentric: 32%
- Cigarette Smoking: 84% in New Zealand Study



- Treatment of VIN
- Surgical excision for solitary lesions
- Wide local excision with 0.5 1cm margin
- /Skinning vulvectomy for large areas or multifocal disease
- Laser excision and Plasmajet excision
- Topical Imiquimod as primary treatment vs adjunctive

Outcomes of 63 women with Warty-Basaloid VIN followed without treatment Jones RW et al. Obstet. Gynecol. 2005;106:1319-26

#### Course variable

- 47 (75%) regressed before tx
- 10 (16 %) progressed to invasive ca before tx
- 6 (10 %) persistent disease
  - 5 young women being followed with tx
  - 1 refused tx >20 years

Treatment outcomes: Warty-Basaloid VIN Jones RW et al. Obstet. Gynecol. 2005;106:1319-26

- Recurrent/persistent disease after treatment
  - Laser vaporization: (39%)
  - Excision: (34%)
    - Margins positive: 50%Margins negative: 15%
- Recurrent / persistent disease after treatment
  - 50% if followed up to 13.7 years
    - Most required 2<sup>nd</sup> tx within 5 years of initial tx
  - Age a factor in need for repeat treatment
    - Age • 24%
    - Age >30 36%

#### Treatment of VIN with 5% Imiquimod Cream

- Immune response modifier
  - Stimulates secretion of cytokines including interferon and and IL-12
  - Effective in treatment of condylomata accuminata
- 10 Studies / 99 Patients with VIN
  - Complete response: 48.5%
  - Partial response (> 50% reduction): 28.3%
  - No cases of invasive cancer during tx or f/u
- Toxicity
  - Local Itching, burning; less common, induration, excoriation, HA, myalgia, flu-like syndrome
- <u>Off label use</u>

Le T, Menard C, Hicks-Boucher W. et.al. Gynecol Oncol 2007;106:579-584

Invasive Ca after Treatment for Warty-Basaloid VIN

Jones RW et al. Obstet. Gynecol. 2005;106:1319-26

- 17 of 312 women treated for VIN developed invasive cancer at least one year after treatment
  - -9 at site of initial tx
    - Median 2.4 years (range 1.1-7 years)
  - 8 at different site
    - Median 13.5 years (range 3-16 years)

## Vulval Disease – VIN and Cancer – Imperial Audit

• Review 2002 – 2012

• Obtained from Histology database

 Reviewec with regards to diagnosis, outcomes, 'other ' conditions

# Results

- 66 patients underwent investigation biopsy/excision
- 8 cases of benign HPV change
- 58 patients had high-grade dysplasia (VIN)
  - 10 (17%) cases were differentiated type VIN
  - 48 (83%) had usual type VIN
  - 27 (47%) had recurrent disease
  - 3 (5%) went onto develop invasive carcinoma
  - 40 (69%) had multicentric dysplasia

# Demographics


Characteristics	n	%
Age (years) mean range	44 21-86	
Nulliparous	27	59%
Multiparous	18	40%
Smoking	18	28%
Alcohol	10	15%
Immunosuppression	19	29%
Preexisting vulval abnormalities	13	20%

Van Seters et al – quotes mean of 46

# Demographics


#### Immunosuppression

- HIV positive
- Renal Transplant
- Renal/Pancreatic transplant
- Immunomodulators
- Steroids



#### **Prior Vuval Abnormality**

- Lichen Sclerosis Lichen Planus
- ■Psoriasis ■Warts
- HSV Other




# Referral

#### Symptoms / Signs (59 patients)

none

- vulval lesion (+/- other symptoms)
- vulval pruritis, soreness, pain (or combination)








93% had symptoms OR a lesion or BOTH

# Referral

• 35 (63%) had abnormal smears on referral



# **Differentiated VIN**


- 10/58 (17%)
  - Average age 56 (range 35-86)
  - No smokers
  - Half were immunosuppressed (4 HIV+, 1 HSV)
    - All 5 patients had multicentric disease
  - 6 had multifocal disease
  - 4 had recurrent disease
    - Intervals of 1, 6, 16 years to recurrence
  - Range of histology :
    - 6 VIN3
    - 1 VIN2, 1 melanocytic change with atypia
    - 1 microinvasive
    - 1 invasive carcinoma at referral-lichen sclerosis
  - Treatment
    - 7 had excisional treatments (average #1.6 (range 1-3))
    - 2 patients had imiquimod and 1 vulvectomy

# Multicentricity

**Multicentric disease** 40 /58 (69%) VIN & CIN (2 areas) 23 /58 (57%) VIN & VAIN/AIN (2 areas, excluding CIN) VIN & CIN & AIN/VAIN (3 areas) VIN & CIN & AIN & VAIN (all 4 areas) N = 2N = 1538% 50% N = 20 7% N = 3

# **Treatment Method**

• 63 patients received some form of treatment or required excisional biopsy



# **Recurrent VIN**

- 27 (47%) + 2 incomplete excisions
  - Range of number of treatments 2-7 (mode 2)
  - Average time to recurrence or development of multicentric disease was 3.2 years (range <1-20 years)</li>
- 5 microinvasive (9%)
  - 2 had VIN2/3 following prior excision for microinvasion

#### 3 (5%) had invasive disease

- Average age 54 (range 33-86)
  - Included 2/4 of lichen sclerosis patients (differentiated type)
  - Had multiple VIN diagnoses, including VIN3
  - All had 1-5 previous excisions, 1 failed IMQ
  - All invasive disease was treated with vulvectomy

# **Vulval Disease**

- Thank you for your attention
- What questions would you like to ask